New business unit brings together specialised scientific, regulatory and commercial expertise to support one of the industry's most advanced GLP-1 development platforms
Zug, Switzerland, 5 October 2026 – Adalvo today announced the launch of a dedicated GLP-1 Business Unit, reinforcing its position as a leading development and commercialisation partner in one of the fastest-growing and most strategically important therapeutic areas worldwide.
The new business unit will be led by Martina Feitzinger, Deputy CEO and Chief Scientific Officer, and brings together specialist expertise across peptide science, formulation development, regulatory affairs, intellectual property, supply chain, quality, programme management and commercial strategy.
The establishment of the unit reflects both the scale of Adalvo's existing GLP-1 activities and the increasing complexity of the next generation of metabolic therapies. As the market evolves beyond first-generation diabetes treatments into broader obesity, cardiometabolic and future peptide-based therapies, successful development requires a unique combination of scientific depth, regulatory expertise and execution capability.
Adalvo has built its GLP-1 platform around these capabilities.
Its portfolio spans semaglutide, tirzepatide and emerging next-wave opportunities, supported by expertise in complex injectable, day-one market entry strategies, global regulatory pathways and intellectual property solutions. The company has already achieved multiple regulatory milestones, approvals and commercial launches across international markets, while continuing to expand its pipeline of future metabolic therapies.
Unlike many organisations approaching the category through a single functional lens, Adalvo combines scientific innovation, development expertise and commercial execution within one integrated platform, enabling partners to navigate the increasingly demanding requirements of global GLP-1 programmes with confidence.
The new business unit creates a dedicated operating model focused entirely on advancing these opportunities, accelerating decision-making, strengthening accountability and ensuring specialised resources are aligned to the company's expanding portfolio and partner needs.
"The GLP-1 category represents one of the most significant therapeutic opportunities of our generation, but success in this space requires much more than access to molecules. It demands deep scientific understanding, regulatory excellence, robust supply strategies and the ability to execute globally.
By creating a dedicated GLP-1 Business Unit, we are bringing together all the expertise required to advance these complex programmes under a single focused structure. This investment strengthens our ability to support partners, accelerate development and expand patient access to these transformative therapies worldwide."
The launch of the dedicated business unit represents the next step in Adalvo's long-term commitment to metabolic health and peptide innovation. With specialist teams, growing global experience and proven execution capabilities across the GLP-1 landscape, Adalvo is uniquely positioned to support partners seeking a scientifically grounded, commercially focused and globally scalable platform for the development and delivery of next-generation therapies.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.